Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: Implication for brain metastasis and metastasis-induced brain damage

Cancer Research

Volumn 72, Issue 1, 2012, Pages 144-153

  Fitzgerald, Daniel P ^a   Subramanian, Preeti ^b   Deshpande, Monika ^b   Graves, Christian ^a   Gordon, Ira ^a   Qian, Yongzhen ^d   Snitkovsky, Yeva ^c   Liewehr, David J ^a   Steinberg, Seth M ^a   Paltán Ortiz, José D ^c   Herman, Mary M ^c   Camphausen, Kevin ^a   Palmieri, Diane ^a   Becerra, S Patricia ^b   Steeg, Patricia S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIGMENT EPITHELIUM DERIVED FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DAMAGE; BRAIN METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL SPECIFICITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METASTASIS INHIBITION; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EYE PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; NEOPLASM METASTASIS; NERVE GROWTH FACTORS; NEURONS; SERPINS;

EID: 84855379661     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1904     Document Type: Article

References (49)

1. Kienast Y, Winkler F. Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 2010;10:1763-77.
2. Platta CS, Khuntia D, Mehta MP, Suh JH. Current treatment strategies for brain metastasis and complications from therapeutic techniques: a review of current literature. Am J Clin Oncol 2009; 33:398-407.
3. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-63.
4. deVries NA, Beijnen JH, Boogerd W, van Tellingen O. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother 2006;6:1199-209. (Pubitemid 44231977)
5. Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 2010;12:748-54.
6. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884-98. (Pubitemid 47328231)
7. Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP. Either called "Chemobrain" or "Chemofog," the longterm chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage 2010;41:126-39.
8. Welzel G, Fleckenstein K, Mai SK, Hermann B, Kraus-Tiefenbacher U, Wenz F. Acute neurocognitive impairment during cranial radiation therapy in patients with intracranial tumors. Strahlenther Onkol 2008;184:647-54.
9. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 2009;7:1438-45.
10. Cai J, Parr C, Watkins G, Jiang WG, Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 2006;12:3510-7.
11. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium- derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A 1993;90:1526-30. (Pubitemid 23058206)
12. Cao W, Tombran-Tink J, Elias R, Sezate S, Mrazek D, McGinnis JF. In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2001;42:1646-52. (Pubitemid 32520760)
13. Cayouette M, Smith SB, Becerra SP, Gravel C. Pigment epitheliumderived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 1999;6:523-32. (Pubitemid 30036622)
14. Jablonski MM, Tombran-Tink J, Mrazek DA, Iannaccone A. Pigment epithelium-derived factor supports normal development of photoreceptor neurons and opsin expression after retinal pigment epithelium removal. J Neurosci 2000;20:7149-57.
15. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemiainduced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci U S A 2001;98: 2593-7. (Pubitemid 32209527)
16. Yabe T, Sanagi T, Yamada H. The neuroprotective role of PEDF: implication for the therapy of neurological disorders. Curr Mol Med 2010;10:259-66.
17. Tombran-Tink J, Mazuruk K, Rodriguez IR, Chung D, Linker T, Englander E, et al. Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. Mol Vis 1996;2:11.
18. Chung C, Doll JA, Gattu AK, Shugrue C, Cornwell M, Fitchev P, et al. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol 2008;48:471-8.
19. Ramirez-Castillejo C, Sanchez-Sanchez F, Andreu-Agullo C, Ferron SR, Aroca-Aguilar JD, Sanchez P, et al. Pigment epithelium-derived factor is a niche signal for neural stem cell renewal. Nat Neurosci 2006;9:331-9. (Pubitemid 43290962)
20. Wang JJ, Zhang SX, Mott R, Chen Y, Knapp RR, Cao W, et al. Antiinflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol 2008;294:F1166-73.
21. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8. (Pubitemid 29329995)
22. Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epitheliumderived factor as a multifunctional antitumor factor. J Mol Med 2007;85:15-22. (Pubitemid 46020939)
23. Hoshina D, Abe R, Yamagishi SI, Shimizu H. The role of PEDF in tumor growth and metastasis. Curr Mol Med 2010;10:292-5.
24. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-76. (Pubitemid 43262032)
25. BilakMM,BecerraSP, Vincent AM, MossBH, AymerichMS, Kuncl RW. Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons. J Neurosci 2002;22:9378-86. (Pubitemid 35356181)
26. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005;65:5144-52. (Pubitemid 40827323)
27. Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, et al. Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res. 2009;15:1655-63.
28. Bernard A, Gao-Li J, Franco CA, Bouceba T, Huet A, Li Z. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium- derived factor. J Biol Chem 2009;284:10480-90.
29. Notari L, Arakaki N, Mueller D, Meier S, Amaral J, Becerra SP. Pigment epithelium-derived factor binds to cell-surface F(1)-ATP synthase. FEBS J 2010;277:2192-205.
30. Notari L, Baladron V, Aroca-Aguilar JD, Balko N, Heredia R, Meyer C, et al. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 2006;281:38022-37. (Pubitemid 46042106)
31. Park K, Lee K, Zhang B, Zhou T, He X, Gao G, et al. Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol 2011;31: 3038-51.
32. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007;67:4190-8. (Pubitemid 46815065)
33. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010;16:5664-78.
34. Seigel GM, Mutchler AL, Imperato EL. Expression of glial markers in a retinal precursor cell line. Mol Vis 1996;2:2.
35. Chung JH, Whiteley M, Felsenfeld G. A 50 element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 1993;74: 505-14. (Pubitemid 23244616)
36. Stratikos E, Alberdi E, Gettins PG, Becerra SP. Recombinant human pigment epithelium-derived factor (PEDF): characterization of PEDF overexpressed and secreted by eukaryotic cells. Protein Sci 1996;5: 2575-82. (Pubitemid 26424870)
37. Solly K, Wang X, Xu X, Strulovici B, Zheng W. Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2004;2:363-72. (Pubitemid 39276278)
38. Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009;15:6148-57.
39. Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009;8:1589-95.
40. Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000;874:123-30.
41. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 2008;25:799-810.
42. Gril B, Palmieri D, Qian Y, Smart D, Ileva L, Liewehr DJ, et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 2011;17: 142-53.
43. Anderson KJ, Miller KM, Fugaccia I, Scheff SW.Regional distribution of fluoro-jade B staining in the hippocampus following traumatic brain injury. Exp Neurol 2005;193:125-30. (Pubitemid 40463274)
44. Frank TC, Nunley MC, Sons HD, Ramon R, Abbott LC. Fluoro-jade identification of cerebellar granule cell and purkinje cell death in the alpha1A calcium ion channel mutant mouse, leaner. Neuroscience 2003;118:667-80. (Pubitemid 36506955)
45. Krinke GJ, Classen W, Vidotto N, Suter E, Wurmlin CH. Detecting necrotic neurons with fluoro-jade stain. Exp Toxicol Pathol 2001;53: 365-72. (Pubitemid 33054902)
46. Kundrotiene J, Wagner A, Liljequist S. Fluoro-Jade and TUNEL staining as useful tools to identify ischemic brain damage following moderate extradural compression of sensorimotor cortex. Acta Neurobiol Exp (Wars) 2004;64:153-62. (Pubitemid 38649376)
47. Mitruskova B, Orendacova J, Racekova E. Fluoro Jade-B detection of dying cells in the SVZ and RMS of adult rats after bilateral olfactory bulbectomy. Cell Mol Neurobiol 2005;25:1255-64.
48. Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Front Biosci 2005;10:2131-49. (Pubitemid 40905288)
49. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008;324:1064-72. (Pubitemid 351397849)